In the long struggle against amyotrophic lateral sclerosis — a disease that has offered patients little more than a measured countdown — Corcept Therapeutics has introduced a complication worth sitting with: a drug that failed by the rules of its own trial yet appears to have kept people alive in numbers that are difficult to dismiss. The DAZALS trial's Phase 2 data, released Friday, showed dazucorilant reducing death risk by 87% at 24 weeks and 84% at one year, even as the study missed its primary endpoint — a paradox that now rests in the hands of regulators, investors, and the patients who
Corcept's ALS Drug Shows 87% Lower Death Risk Despite Missing Primary Endpoint
ALS patients treated with dazucorilant experienced significantly improved survival rates, reducing mortality risk in a progressive fatal neurodegenerative disease.
A drug that can reduce mortality risk by more than 80 percent
Mark
The drug missed its primary endpoint. Why did the stock go up?
Mimi
Because patients on the 300-milligram dose lived substantially longer. An 87% reduction in death risk is not a small thing, even if it wasn't the specific measure the company had promised to hit.
Mark
But isn't a missed primary endpoint a failure?
Mimi
Technically, yes. But in ALS, where there are almost no effective treatments, a drug that demonstrably extends life has real value. The question is whether the FDA sees it the same way.
Mark
The company also missed earnings and revenue targets. How does that fit?
Mimi
It doesn't, cleanly. The clinical data is encouraging, but the financial performance suggests the market isn't convinced yet. The stock is trading at a premium, and momentum is weak.
Mark
What does this mean for patients?
Mimi
If the drug gets approved, it could extend survival by months or years in a disease that kills you. That's not a cure, but it's not nothing either.
Mark
And if it doesn't get approved?
Mimi
Then the data becomes a footnote. The company has to convince regulators that missing the primary endpoint doesn't matter because the survival benefit is real and clinically meaningful.
O Pulso
- A drug that technically failed its own trial is nonetheless showing mortality reductions above 80%, creating a rare and uncomfortable tension between regulatory definitions of success and the lived reality of patients surviving longer.
- Corcept's stock rose 3.37% on the news, but beneath that optimism lies a financial report that missed earnings by nearly half — 30 cents per share lost versus the 16-cent loss expected — and fell nearly $28 million short of revenue forecasts.
- The company responded to the mixed picture not with retreat but with raised 2026 sales guidance, a confident posture that analysts are watching skeptically given weak momentum scores and a valuation premium relative to peers.
- The central unresolved question is whether regulators will treat dramatic survival data as sufficient grounds for approval when the pre-specified primary endpoint was not met — a decision that carries enormous weight for ALS patients whose disease typically claims lives within two to five years of diagnosis.
In the long struggle against amyotrophic lateral sclerosis — a disease that has offered patients little more than a measured countdown — Corcept Therapeutics has introduced a complication worth sitting with: a drug that failed by the rules of its own trial yet appears to have kept people alive in numbers that are difficult to dismiss. The DAZALS trial's Phase 2 data, released Friday, showed dazucorilant reducing death risk by 87% at 24 weeks and 84% at one year, even as the study missed its primary endpoint — a paradox that now rests in the hands of regulators, investors, and the patients who have the most to lose from how it is resolved.
Corcept Therapeutics released Phase 2 results Friday for dazucorilant, its experimental ALS drug, and the data arrived in a shape that defied easy interpretation. The trial missed its primary endpoint — the specific measure of success the company had committed to before the study began — yet patients taking the 300-milligram daily dose lived substantially longer than those on placebo. At 24 weeks, death risk fell by 87%. At one year, the benefit held at 84%. Even two years out, patients on the higher dose showed a 61% lower risk of death compared to those on placebo or the lower dose. The stock closed up 3.37% at $48.09, a modest but telling response to a result that was genuinely promising despite its technical failure.
For a disease like ALS — progressive, incurable, and typically fatal within two to five years of diagnosis — data of this magnitude carries weight that transcends clinical trial conventions. The question now before regulators is whether survival outcomes this consistent can justify approval even when the pre-defined endpoint was not reached. Corcept moved forward as if the answer might be yes, raising its 2026 sales guidance despite the mixed clinical picture.
The financial backdrop, however, complicated the narrative. The company reported a loss of 30 cents per share against an expected 16-cent loss, and revenue of $164.9 million fell well short of the $192.51 million analysts had forecast. Corcept carries a strong balance sheet — a meaningful distinction in biotech — but analysts noted weak momentum and a valuation premium that may be difficult to sustain without broader market support. The company now faces the dual challenge of convincing regulators that its survival data is enough, and convincing investors that its commercial foundation can hold.
Corcept Therapeutics released Phase 2 data on Friday that painted a paradoxical picture: the company's experimental ALS drug failed to hit its primary target, yet patients taking it lived substantially longer than those on placebo. The stock rose 3.37% on the news, closing at $48.09, a reaction that reflected the genuine promise buried inside an otherwise messy clinical result.
The drug in question is dazucorilant, a compound designed to treat amyotrophic lateral sclerosis—the progressive, incurable disease that destroys motor neurons in the brain and spinal cord, leaving patients paralyzed and ultimately unable to breathe on their own. The DAZALS trial followed patients over 24 weeks of treatment, then tracked many of them for years afterward. What emerged was striking: patients receiving 300 milligrams of dazucorilant daily showed an 87% reduction in death risk by the end of the initial treatment window. At one year, that benefit held at 84%. Even at two years, patients who had continued on the 300-milligram dose showed a 61% lower risk of death compared to those who received placebo or the lower 150-milligram dose.
Yet the trial did not achieve what regulators call the primary endpoint—the specific measure of efficacy the company had promised to hit before the study began. This is the kind of result that can confound investors and doctors alike. The drug appears to be keeping people alive, measurably and substantially, but not in the way the researchers had initially defined success. Corcept nonetheless moved forward with confidence, raising its sales guidance for 2026 despite the mixed clinical picture.
The financial results, however, told a different story. Corcept reported a loss of 30 cents per share, worse than the 16-cent loss analysts had expected. Revenue came in at $164.9 million, falling short of the $192.51 million consensus forecast. The company is profitable on its balance sheet—a genuine strength in an industry where many biotech firms burn cash relentlessly—but the momentum is weak. Benzinga's analysis ranked the stock as trading at a steep premium relative to peers, with weak momentum scores suggesting the market may not sustain enthusiasm without broader support.
For ALS patients and their families, the data offers something more tangible than stock movements: a potential path toward extended survival in a disease that has historically offered none. ALS typically progresses over two to five years from diagnosis to death. A drug that can reduce mortality risk by more than 80 percent, even if it missed a technical endpoint, represents a meaningful intervention. The question now is whether regulators will view the survival data as sufficient justification for approval, and whether Corcept can translate clinical promise into commercial success despite the financial headwinds.
Citações Notáveis
Patients receiving 300 milligrams of dazucorilant daily showed an 87% reduction in death risk by the end of the initial treatment window— DAZALS trial data
Quer a matéria completa?
Leia o original em Benzinga ↗
Health & Medicine